Frontiers in Genetics (Mar 2021)

Precision Population Medicine in Primary Care: The Sanford Chip Experience

  • Kurt D. Christensen,
  • Kurt D. Christensen,
  • Kurt D. Christensen,
  • Megan Bell,
  • Carrie L. B. Zawatsky,
  • Carrie L. B. Zawatsky,
  • Lauren N. Galbraith,
  • Robert C. Green,
  • Robert C. Green,
  • Robert C. Green,
  • Robert C. Green,
  • Allison M. Hutchinson,
  • Leila Jamal,
  • Leila Jamal,
  • Jessica L. LeBlanc,
  • Jennifer R. Leonhard,
  • Michelle Moore,
  • Lisa Mullineaux,
  • Natasha Petry,
  • Natasha Petry,
  • Dylan M. Platt,
  • Sherin Shaaban,
  • Sherin Shaaban,
  • April Schultz,
  • April Schultz,
  • Bethany D. Tucker,
  • Joel Van Heukelom,
  • Joel Van Heukelom,
  • Elizabeth Wheeler,
  • Emilie S. Zoltick,
  • Catherine Hajek,
  • Catherine Hajek,
  • on behalf of the Imagenetics Metrics Team,
  • Baye Jordan,
  • Bell Megan,
  • Deberg Kristen,
  • Forred Benjamin,
  • Free Colette,
  • Hajek Catherine,
  • Heukelom Joel Van,
  • Hopp Ashley,
  • Hutchinson Allison,
  • Lees Ryne,
  • Leonhard Jennifer,
  • Massmann Amanda,
  • Moore Michelle,
  • Mroch Amelia,
  • Petry Natasha,
  • Platt Dylan,
  • Royer Erin,
  • Schultz April,
  • Sincan Murat,
  • Tucker Bethany,
  • Wheeler Elizabeth,
  • Christensen Kurt,
  • Galbraith Lauren,
  • LeBlanc Jessica,
  • Walsh Ryan,
  • Zoltick Emilie,
  • Green Robert,
  • Preys Charlene,
  • Zawatsky Carrie,
  • Mullineaux Lisa,
  • Jamal Leila

DOI
https://doi.org/10.3389/fgene.2021.626845
Journal volume & issue
Vol. 12

Abstract

Read online

Genetic testing has the potential to revolutionize primary care, but few health systems have developed the infrastructure to support precision population medicine applications or attempted to evaluate its impact on patient and provider outcomes. In 2018, Sanford Health, the nation’s largest rural nonprofit health care system, began offering genetic testing to its primary care patients. To date, more than 11,000 patients have participated in the Sanford Chip Program, over 90% of whom have been identified with at least one informative pharmacogenomic variant, and about 1.5% of whom have been identified with a medically actionable predisposition for disease. This manuscript describes the rationale for offering the Sanford Chip, the programs and infrastructure implemented to support it, and evolving plans for research to evaluate its real-world impact.

Keywords